Diana Berrent Nadia
Key Findings: Both Pfizer and Moderna had significant fewer breakthrough symptomatic cases Far fewer J&J recipients who had breakthrough symptomatic cases ended up with Long Covid 2/
Diana Berrent Nadia
Key Findings: Both Pfizer and Moderna had significant fewer breakthrough symptomatic cases Far fewer J&J recipients who had breakthrough symptomatic cases ended up with Long Covid 2/